Impact BioMedical Inc. (IBO) stock

IBONYSEPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 5/30

$3.06+0.38 (+14.18%)

Close on Oct 19, 2026Market cap $26.14MP/E –Yield –

Impact BioMedical total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Impact BioMedical's total debt was $7.97M at Sep 30, 2024.

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q3 FY2024	Sep 30, 2024	$7.97M	–
Q3 FY2023	Sep 30, 2023	$11.90M	–

Parsed from the XBRL in Impact BioMedical's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-12.67 reverse split on Nov 9, 2026
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is IBO.

Advertisement
300 × 250

See a number that looks wrong?